RP# [002]

Related by string. rp# . RP# [003] . Rp# [002] . Rp# [001] . RP# [001] * * Rp# trillion [001] . Rp# trillion [002] . Rp# billion . HP rp# . HP rp# Point . HP rp# Cluster . HP rp# POS *

Related by context. All words. (Click for frequent words.) 65 volociximab 64 vascular disrupting agent 64 DB# [003] 63 Amrubicin 63 TRX# 63 vidofludimus 63 Phase Ib clinical 62 elotuzumab 62 Archexin 62 generation purine nucleoside 62 PN# [001] 62 Traficet EN 62 histone deacetylase HDAC inhibitor 62 nucleoside analog 62 liposomal formulation 62 mertansine 62 Onconase 62 subcutaneous formulation 61 BAY #-# 61 GV# [001] 61 alemtuzumab Campath 61 HuMax EGFr 61 mTOR inhibitor 61 TH# [003] 61 HuMax CD4 61 Lenalidomide 61 Dacogen injection 61 paclitaxel Taxol 61 pertuzumab 60 Tarceva erlotinib 60 XL# [003] 60 ongoing Phase 1b 60 Azedra 60 angiogenesis inhibitor 60 Tarvacin 60 axitinib 60 BRIM2 60 Treanda 60 Proxinium TM 60 Daclizumab 60 PrevOnco ™ 60 TG# [001] 60 ASA# 60 rNAPc2 60 Avastin bevacizumab 60 Erbitux cetuximab 60 Allovectin 7 60 Pemetrexed 60 anticancer agent 60 Clevudine 60 Erlotinib 60 Telcyta 60 Aflibercept 60 RH1 60 radiation sensitizer 59 OXi# 59 tanespimycin 59 Gleevec imatinib mesylate 59 proteasome inhibitor bortezomib 59 Dasatinib 59 ZACTIMA 59 Tarceva TM 59 Dapagliflozin 59 IMA# 59 small molecule glucokinase 59 somatostatin analogue 59 CEQ# 59 anticancer compound 59 Zybrestat 59 murine monoclonal antibody 59 orally bioavailable 59 entinostat 59 RhuDex ® 59 IFN α 59 docetaxel Taxotere R 59 seliciclib CYC# 59 humanized monoclonal antibody 59 RG# [001] 59 Mipomersen 59 phase IIa clinical 59 PSMA ADC 59 MAGE A3 ASCI 59 MEK inhibitor 59 elacytarabine 59 Pertuzumab 59 PLX# 59 investigational humanized monoclonal antibody 59 LymphoStat B TM 59 tumor xenograft models 58 atacicept 58 HGS# 58 Phase 1b clinical 58 HuMax CD# 58 Tocosol Paclitaxel 58 Pralatrexate 58 Davanat 58 Panzem R NCD 58 Amplimexon 58 PEGPH# 58 Boceprevir 58 ZD# [001] 58 MabCampath 58 Phase Ib study 58 EndoTAG TM -1 58 epothilone 58 Hycamtin ® 58 Sym# 58 sorafenib Nexavar 58 Phase IIa trials 58 multicenter Phase II 58 etanercept Enbrel 58 oral prodrug 58 Epratuzumab 58 histone deacetylase inhibitor 58 PDE4 inhibitor 58 Satraplatin 58 Onalta ™ 58 proteasome inhibitor 58 OncoVEX GM CSF 58 Factor VIIa 58 Phase Ib clinical trials 58 protein kinase inhibitor 58 oral antiviral 58 Saforis 58 Aplidin 58 Insegia 58 bortezomib Velcade ® 58 ATL# [001] 58 AEZS 58 thymalfasin 58 amrubicin 58 polymerase inhibitor 58 vemurafenib 58 Xanafide 58 reslizumab 58 TNF Tumor Necrosis Factor 58 phase IIb clinical 58 Ceflatonin 58 fipamezole 58 DermaVir Patch 58 ularitide 58 PEG SN# 58 Marqibo TM 58 Glufosfamide 58 HQK 58 AKT inhibitor 58 Everolimus 58 Maraviroc 58 BRAF inhibitor 58 HCV protease inhibitor 58 metaglidasen 58 EOquin TM 58 Apoptone 58 drug conjugate 58 CA4P 58 thalidomide Thalomid 58 MGCD# [001] 58 Annamycin 58 depsipeptide 58 dacetuzumab 58 cediranib 58 CYC# 57 Nexavar ® 57 Trastuzumab 57 Vandetanib 57 humanized monoclonal 57 gemcitabine Gemzar ® 57 Reolysin 57 Debio 57 methylnaltrexone 57 BIBW 57 perifosine 57 VELCADE melphalan 57 Actilon 57 Aptivus ® 57 docetaxel Taxotere ® 57 Polymer Microspheres 57 regorafenib 57 cilengitide 57 UPLYSO 57 signal transduction inhibitor 57 FK# 57 AS# amonafide L malate 57 ixabepilone 57 TRC# 57 Rituximab 57 phase Ib 57 phase IIb 57 Taxotere ® 57 SNT MC# 57 Phase IIIb clinical 57 R#/MEM 57 phase IIa 57 receptor tyrosine kinase inhibitor 57 CCX# 57 DNA intercalator 57 Imprime PGG 57 Gleevec resistant 57 BrachySil 57 MNTX 57 Aurora Kinase 57 Virulizin 57 AZILECT R 57 enzastaurin 57 XmAb# 57 corticosteroid dexamethasone 57 farletuzumab 57 Pradefovir 57 JAK inhibitor 57 gefitinib Iressa 57 immunotherapeutic agent 57 Emselex 57 YONDELIS 57 trabectedin 57 Alvesco R 57 Clolar ® 57 EndoTAG 57 INCB# [001] 57 IV Busulfex 57 zanolimumab 57 metastatic renal cell carcinoma 57 Safinamide 57 PRO# [003] 57 glufosfamide 57 TASQ 57 Neuvenge 57 adalimumab Humira 57 cetuximab Erbitux ® 57 Interferon beta 57 Phase 1a clinical 57 daclizumab 57 tyrosine kinase inhibitor 57 amifampridine phosphate 57 HuLuc# 57 lintuzumab 57 TLR8 agonist 57 huC# DM4 57 ocrelizumab 57 oral ridaforolimus 57 SCH # 57 Gemcitabine 57 bazedoxifene selective estrogen receptor 57 nucleoside reverse transcriptase inhibitor 57 temsirolimus Torisel ® 57 HGS ETR2 57 Phase 1b 57 EOquin 57 AQ4N 57 Solazed 57 HGS ETR1 57 humanized anti 57 PEGylated Fab fragment 57 XL# XL# 57 NP2 57 Fx #A 57 Targretin 57 TELCYTA 57 PD LID 56 ORENCIA ® 56 Natalizumab 56 PrevOnco 56 Phase IIb clinical 56 IMP# 56 Nexavar sorafenib 56 Radezolid 56 Aplidin R 56 CCR5 antagonist 56 virus HCV protease inhibitor 56 AT# [002] 56 Hsp# Inhibitor 56 neratinib 56 SRT# [003] 56 NXL# 56 ProSavin 56 OPAXIO 56 ONCASPAR 56 MAP# 56 ProLindac 56 paclitaxel carboplatin 56 solithromycin 56 Ocrelizumab 56 Perifosine 56 Dalbavancin 56 Tarvacin TM 56 Viramidine 56 pegylated liposomal doxorubicin 56 fosbretabulin 56 IMC #B 56 targeting CD# 56 rilonacept 56 cetuximab Erbitux R 56 multi kinase inhibitor 56 LAF# 56 romidepsin 56 pomalidomide 56 obatoclax 56 PF # [001] 56 LEP ETU 56 Onalta 56 cetuximab Erbitux 56 teriflunomide 56 antiplatelet agent 56 selectively binds 56 RhuDex 56 sargramostim 56 Vidaza R 56 investigational immunotherapy 56 Cloretazine ® 56 CDK inhibitor 56 Bortezomib 56 lumiliximab 56 mitogen activated ERK kinase 56 RAV# 56 SYN# 56 GRN#L 56 SIR Spheres 56 SU# [003] 56 Gemzar ® 56 Troxatyl 56 Interferon alpha 56 dose escalation clinical 56 pan HDAC inhibitor 56 crizotinib PF # 56 Keppra XR 56 vinorelbine tartrate 56 HCD# [002] 56 erlotinib Tarceva ® 56 Velcade bortezomib 56 GA# [003] 56 R#/MEM # 56 YONDELIS R 56 MVA BN R 56 octreotide acetate 56 MyVax R 56 lapatinib Tykerb 56 Capesaris 56 BNC# 56 Sutent sunitinib 56 Revlimid lenalidomide 56 oral proteasome inhibitor 56 ASONEP 56 GW# [003] 56 Virulizin R 56 IMC A# 56 ridaforolimus 56 APOPTONE 56 preclinical efficacy 56 L BLP# 56 iniparib 56 eniluracil 56 Cloretazine R VNP#M 56 Ixempra 56 bevacizumab Avastin 56 methionine aminopeptidase 56 Civacir 56 novel VDA molecule 56 Laquinimod 56 GlycoPEG GCSF 56 IRX 2 56 Copegus ribavirin 56 AEG# 56 PXD# 56 PRT# 56 KB# [004] 56 refractory chronic lymphocytic 56 Panitumumab 56 triphendiol 56 FOLOTYN ® 56 GAMMAGARD 56 Enzastaurin 56 anti CD3 monoclonal 56 Phase 2b clinical trials 56 ZOLINZA 56 immunomodulator 56 alkylating agent 56 randomized controlled Phase 56 forodesine 56 Temsirolimus 56 Abatacept 56 Pennsaid R 56 phase 2a 56 ORENCIA R 56 SERMs 56 NPC 1C 56 antisense inhibitor 56 Blinatumomab 56 MEK inhibitors 56 Cimzia certolizumab pegol 56 phase Ib clinical 56 metastatic hormone refractory 56 eprotirome 56 CytoFab 56 Firazyr 56 Ceplene/IL-2 56 vascular disrupting agents 56 Abiraterone 56 Orazol 56 Asentar 56 anti angiogenic agent 56 ONX 56 RoACTEMRA 56 humanized antibody 56 Kissei Pharmaceutical 56 Pazopanib 56 Voreloxin 56 Evoltra 56 ofatumumab 56 CBLC# 56 intranasal formulation 56 EZN 56 Phase 1b clinical trials 56 sunitinib malate 56 nucleotide analog 55 mapatumumab 55 Zolinza 55 HDAC Inhibitor 55 LymphoStat B belimumab 55 TBC# 55 multiple myeloma MM 55 ATL/TV# 55 Phase IIa trial 55 antibody MAb 55 MGd 55 zalutumumab 55 evaluating tivozanib 55 TG# [003] 55 DEB# 55 Panzem 55 REG2 55 HSP# inhibitor 55 Alocrest 55 Telatinib 55 antisense oligonucleotide 55 alvespimycin 55 brivaracetam 55 Aurora kinase inhibitor 55 Neulasta ® 55 Quinamed 55 SAR# [004] 55 Campath 55 elesclomol 55 octreotide implant 55 PROMACTA 55 Phase 2a trial 55 DAVANAT 55 Phase 2b clinical 55 Tanespimycin 55 Fludara 55 trastuzumab Herceptin 55 EGFR HER2 55 bardoxolone 55 Interferon beta 1a 55 HyACT 55 Vivecon 55 renin inhibitor 55 ISTODAX 55 deforolimus 55 selective kinase inhibitor 55 Omnitarg 55 Phase Ib 55 PEG Interferon lambda 55 OvaRex ® MAb 55 HDACi 55 FTY# 55 Vidaza azacitidine 55 Phase IIa clinical 55 Cimzia ® certolizumab pegol 55 ATL# [002] 55 Ofatumumab 55 KNS # 55 opioid induced bowel dysfunction 55 TEMODAL 55 Angiolix 55 posaconazole 55 HE# [002] 55 baminercept 55 Afatinib 55 Phase 2b trial 55 BRIM3 55 NGX# 55 AZD# 55 LHRH antagonist 55 Preclinical studies suggest 55 Aclidinium 55 huN# DM1 55 vandetanib 55 Phase Ib II 55 Arimidex anastrozole 55 OMP #M# 55 Zactima 55 TNFerade 55 GRNVAC1 55 ONTAK 55 Tyrima 55 Herceptin trastuzumab 55 preclinically 55 ADAGIO study 55 erlotinib Tarceva 55 Personalized Immunotherapy 55 CoFactor 55 Trofex 55 dirucotide 55 boosted protease inhibitor 55 Janus Kinase 55 FOLFOX6 55 Denufosol 55 Anticalin ® 55 Anticalin R 55 ThermoDox ® 55 2DG 55 KB# [002] 55 mu opioid receptor antagonist 55 EP #R 55 oral anticancer 55 carfilzomib 55 Dabigatran etexilate 55 PRX# 55 Aurexis 55 Canvaxin 55 samalizumab 55 Coversyl 55 OHR/AVR# 55 Marqibo 55 carboplatin paclitaxel 55 adecatumumab MT# 55 adecatumumab 55 Aurora kinase 55 ganetespib 55 mRCC 55 belinostat 55 Removab 55 trastuzumab DM1 T DM1 55 Phase #b/#a clinical 55 sipuleucel T 55 riociguat 55 resminostat 55 SUTENT ® 55 CYT# 55 TLR9 agonist 55 ThermoDox R 55 Vidofludimus 55 paclitaxel Taxol ® 55 tiapamil 55 immunomodulatory therapy 55 Tesetaxel 55 biologic therapy 55 lurasidone 55 registrational 55 Thiarabine 55 Fc fusion protein 55 cannabinor 55 Pirfenidone 55 novel prodrug 55 Pixantrone 55 Immunotherapeutic 55 Avanafil 55 antitumor activity 54 XYOTAX TM 54 oral Xeloda 54 tivozanib 54 antisense drug 54 ceftazidime 54 PNP inhibitor 54 OvaRex R 54 picoplatin 54 aurora kinase 54 SGLT2 inhibitors 54 CD# monoclonal antibody 54 PI3K inhibitor 54 Intravenous CP 54 Fodosine 54 ADVEXIN 54 PI3K/Akt pathway inhibitor 54 BiTE R 54 Virulizin ® 54 PF # [002] 54 Vernakalant 54 ocular formulation 54 HIV integrase inhibitor 54 Bavituximab 54 R roscovitine 54 selective modulator 54 TAT# 54 PLK1 SNALP 54 ALN TTR 54 docetaxel chemotherapy 54 dasatinib Sprycel 54 PCK# 54 Azacitidine 54 TRX1 54 targeted radiotherapeutic 54 MT# [002] 54 atrasentan 54 IAP inhibitor 54 NU# [001] 54 temsirolimus 54 mRNA antagonists 54 RSD# 54 administered subcutaneously 54 Plicera 54 Golimumab 54 Azedra TM 54 oral FTY# 54 HCV protease inhibitors 54 pain palliation 54 Antisense 54 vascular disrupting 54 VEGF receptor 54 Evoltra ® 54 nucleoside polymerase inhibitor 54 CDP# 54 Argatroban 54 DACH platinum 54 Darusentan 54 XL# XL# XL# 54 Cimzia TM 54 Akt inhibitor 54 panitumumab Vectibix 54 PKC# 54 proteasome inhibitors 54 CTCE 54 OncoVEX 54 AZILECT ® 54 beta 1a 54 bortezomib Velcade 54 BCX# 54 melphalan prednisone 54 pradefovir 54 Bicifadine 54 Tasimelteon 54 DCVax R 54 Lubiprostone 54 anti EGFR antibody 54 subcutaneously administered 54 metastatic CRC 54 ELACYT 54 selective agonist 54 multitargeted 54 danoprevir 54 RITUXAN 54 bevacizumab Avastin ® 54 Vectibix 54 bendamustine 54 Nanobody 54 telbivudine 54 PEGylated interferon 54 pharmacodynamic properties 54 Cloretazine VNP#M 54 Darunavir 54 Cleviprex TM clevidipine 54 budesonide foam 54 Panzem R 54 CLL SLL 54 anti CD3 54 Sorafenib 54 Tezampanel 54 trastuzumab DM1 54 Onco TCS 54 oxidative stress inducer 54 Hsp# inhibitor 54 dasatinib Sprycel ® 54 Fulvestrant 54 novel anticancer 54 TRO# 54 MT# MEDI 54 ZYBRESTAT 54 Onrigin 54 S/GSK# 54 ALD# 54 IMGN# 54 metastatic colorectal 54 Votrient 54 Bruton tyrosine kinase Btk 54 CB# [002] 54 BAL# [002] 54 Uvidem 54 ASTEROID 54 systemically administered 54 Ganciclovir 54 telomerase therapeutic 54 PANVAC VF 54 mTOR inhibitors 54 Dacogen decitabine 54 EP# [003] 54 ARQ 54 nitric oxide donating prostaglandin 54 ENMD # 54 otelixizumab 54 AVE# 54 GED aPC 54 tosedostat 54 TYKERB 54 UVIDEM 54 Delafloxacin 54 Guanilib 54 Grb 2 54 VA# [002] 54 hypoxia selective 54 Carfilzomib 54 drug eluting coronary stent 54 pharmacokinetic PK 54 personalized immunotherapy 54 pharmacokinetic PK study 54 Phase III clinical 54 Novel Oral 54 cangrelor 54 BZL# 54 novel synthetic peptide 54 investigational monoclonal antibody 54 efalizumab 54 SPC# [001] 54 teduglutide 54 Soliris eculizumab 54 Genentech Rituxan 54 Xerecept 54 SAR# [002] 54 CG# [003] 54 Elagolix 54 BXT # 54 Initiate Phase 54 Silodosin 54 relapsed multiple myeloma 54 bavituximab 54 DU #b 54 Phase 2a 54 custirsen 54 Pfizer Sutent 54 Anidulafungin 54 ALVESCO R 54 Alfimeprase 54 imatinib Gleevec ® 54 Elesclomol 54 ACAPODENE 54 standard chemotherapy regimen 54 Zarnestra 54 TASKi2 54 IMiD 54 trastuzumab emtansine T DM1 54 ALS #-# 54 investigational compound 54 combinability 54 rFIXFc 54 Ceftaroline 54 favorable pharmacokinetic profile 54 fostamatinib 54 platinum refractory 54 CIMZIA TM 54 TroVax 54 pioglitazone HCl 54 HCV polymerase 54 ZK EPO 54 Phase 2b 54 chimeric monoclonal antibody 54 tesmilifene 54 ARIKACE 54 Vaprisol 53 Solazed TM 53 Darinaparsin 53 Cloretazine R 53 Aliskiren 53 LY# [002] 53 kinase inhibitor 53 satraplatin 53 KRN# 53 cathepsin K inhibitor 53 Theratope 53 Bezielle 53 NVA# 53 Reverset 53 Abbokinase 53 IL# PE#QQR 53 phase IIb trial 53 apricitabine 53 Crizotinib 53 EGS# 53 BrachySil TM 53 Scancell 53 Vitaxin 53 palonosetron 53 molecularly targeted 53 DG# [001] 53 CLORETAZINE TM VNP#M 53 Ventavis 53 Xeloda ® 53 talabostat 53 ruxolitinib 53 IRESSA 53 CD3 monoclonal antibody 53 ADP receptor antagonist 53 alpha#beta# integrin 53 ToGA 53 Catena ® 53 nitazoxanide 53 Vicriviroc 53 CYT# potent vascular disrupting 53 generation antisense 53 Androxal TM 53 Aviptadil 53 AP# [003] 53 ON #.Na 53 Spiegelmer ® 53 Xinlay 53 phosphatidylserine PS targeting 53 Phase #b/#a 53 pharmacokinetics PK 53 bendamustine HCl 53 Angiocept 53 TELINTRA 53 apaziquone 53 NP2 Enkephalin 53 TAFA# 53 ARC# [002] 53 ARC# [001] 53 sublingual formulation 53 Lupuzor 53 GLP toxicology studies 53 Hexvix 53 Humira adalimumab 53 Phase 2b study 53 mGluR2 NAM 53 metastatic castration resistant 53 veltuzumab 53 rHuPH# 53 Chemophase 53 tenofovir Viread 53 SUTENT 53 idarubicin 53 modulator SERM 53 BEMA TM Fentanyl 53 Amigal 53 Muraglitazar 53 HER3 53 Recombinant Human 53 Æterna Zentaris 53 Zelrix 53 sodium glucose cotransporter 53 Cethrin R 53 midstage clinical 53 Factor Xa inhibitor 53 Tocilizumab 53 dose escalation trial 53 TroVax ® 53 CVac 53 ILLUMINATE 53 Solulin 53 Tarmogen 53 CCX# B 53 ancrod 53 Xeloda capecitabine 53 fluticasone furoate 53 MF# [002] 53 demonstrated antitumor activity 53 Arcalyst 53 GAP #B# 53 protein tyrosine phosphatase 1B 53 investigational integrase inhibitor 53 novel histone deacetylase 53 aprepitant 53 darinaparsin ZIO 53 Angiotensin Converting Enzyme 53 dexpramipexole 53 Talabostat 53 compound perifosine 53 SCCHN 53 ulimorelin 53 PEGylated anti 53 Rasilez Tekturna 53 Ambrisentan 53 tranilast 53 Adenoma Prevention 53 VEGF Trap 53 Aloxi injection 53 CCR2 53 ARIKACE ™ 53 ND# [002] 53 Ceflatonin R 53 PI3K/mTOR 53 Combination REOLYSIN R 53 Eculizumab 53 Atrasentan 53 Raptiva ® 53 TLK# 53 selective antagonist 53 phase IIb study 53 rasagiline tablets 53 FLT3 53 tafamidis 53 recurrent NSCLC 53 TNFα 53 randomized Phase IIb 53 CD# antibody [001] 53 Randomized Phase 53 dyskinesia PD LID 53 Urocidin 53 Omacetaxine 53 antifibrotic 53 omacetaxine mepesuccinate 53 MOZOBIL 53 Phase 2a clinical 53 Locked Nucleic Acid LNA 53 Lixivaptan 53 FOLFIRI 53 FVIIa 53 Phenoptin 53 atazanavir Reyataz 53 Raltegravir 53 Rebif ® 53 alemtuzumab MS 53 Alemtuzumab 53 orally administered inhibitor 53 trodusquemine 53 Relivar 53 novel topoisomerase 53 celgosivir 53 TMC# [002] 53 PRECISE 53 nucleoside analogue 53 recombinant adeno associated 53 Chemokine Receptor 53 Orally administered 53 CLL8 53 REP# 53 Methylnaltrexone 53 CG# [001] 53 Randomized Phase II 53 clofarabine 53 Elacytarabine 53 sunitinib Sutent 53 decitabine 53 TACI Ig 53 nucleotide analogue 53 AMPA kainate 53 TORISEL 53 BENLYSTA ® 53 LUX Lung 53 novel oral anticoagulant 53 Anavex #-# 53 MKC# MKC# PP 53 IND submission 53 6R BH4 53 refractory multiple myeloma 53 registrational trial 53 PSN# [002] 53 Oglemilast 53 vinca alkaloid 53 inhibitor RG# 53 aflibercept 52 Phase IIb trials 52 BiTE 52 Doxil ® 52 iclaprim 52 MetMAb 52 XMT 52 Pimavanserin 52 potent topoisomerase II 52 PEP# [003] 52 seliciclib 52 Olaparib 52 Synavive 52 oral anticoagulant 52 investigational oral 52 Phase IIb 52 Actemra 52 RLY# 52 imetelstat 52 galiximab 52 Phase 1a 52 CIMZIA ™ 52 novel nucleoside analog 52 placebo controlled Phase 52 maximally tolerated dose 52 generation nucleoside analog 52 Tavocept 52 assessing T DM1 52 E1 INT TM 52 Phase IIB 52 AV HALT 52 PDL# 52 NP# [002] 52 thetreatment 52 HER2 positive metastatic breast 52 blinatumomab 52 tarenflurbil 52 Ramoplanin 52 TRIOLEX 52 Doxorubicin 52 mGluR5 negative 52 QLT# 52 PREOS 52 Pharmacokinetic studies 52 Cannabinor 52 tremelimumab 52 Phase IIb clinical trials 52 Firdapse 52 oral rivaroxaban 52 iroxanadine 52 Romidepsin 52 pharmacokinetic profile 52 Exherin TM

Back to home page